technology

press releases

Date Title and Summary Additional Formats
Toggle Summary - Data presented at AAN Annual Meeting demonstrate eptinezumab further reduces migraine risk following the third and fourth quarterly infusions - More than 50% of patients achieved a 75% reduction or greater of migraine days BOTHELL, Wash. , April 24, 2018 (GLOBE NEWSWIRE) -- Alder View HTML
Toggle Summary BOTHELL, Wash. , April 23, 2018 (GLOBE NEWSWIRE) -- Alder Biopharmaceuticals, Inc. , (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Eric Carter , Ph.D., M.D., has been named Interim Chief Medical View HTML
Toggle Summary PROMISE 2 Phase 3 study selected for Emerging Science clinical trials plenary presentation session on April 24, 2018 BOTHELL, Wash. , April 18, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for View HTML
Toggle Summary Continues to Build Executive Team and Position Company for Next Stage of Growth and Development BOTHELL, Wash. , April 16, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) (“Alder” or the “Company”), a biopharmaceutical company focused on developing novel therapeutic antibodies View HTML
Toggle Summary BOTHELL, Wash. , March 20, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Paul B. Cleveland , a member of the Company’s Board of Directors, has View HTML
Toggle Summary BOTHELL, Wash. , March 05, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Mark J. View HTML
Toggle Summary –    Strong cash position to support eptinezumab development through approval and commercial launch   – –    Recently reported pivotal PROMISE 2 top-line data in chronic migraine demonstrates eptinezumab significantly reduced migraine risk in patients, met all primary and key secondary endpoints View HTML
Toggle Summary BOTHELL, Wash. , Feb. 19, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its fourth quarter and year-end 2017 financial and View HTML
Toggle Summary BOTHELL, Wash. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today that the underwriters of its previously announced offering of 2.50% View HTML
Toggle Summary BOTHELL, Wash. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Randall C. View HTML